SG11202109587TA - Extracellular vesicle conjugates and uses thereof - Google Patents

Extracellular vesicle conjugates and uses thereof

Info

Publication number
SG11202109587TA
SG11202109587TA SG11202109587TA SG11202109587TA SG 11202109587T A SG11202109587T A SG 11202109587TA SG 11202109587T A SG11202109587T A SG 11202109587TA SG 11202109587T A SG11202109587T A SG 11202109587TA
Authority
SG
Singapore
Prior art keywords
extracellular vesicle
vesicle conjugates
conjugates
extracellular
vesicle
Prior art date
Application number
Other languages
English (en)
Inventor
Russell E Mcconell
Sriram Sathyanarayanan
Original Assignee
Codiak Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codiak Biosciences Inc filed Critical Codiak Biosciences Inc
Publication of SG11202109587TA publication Critical patent/SG11202109587TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202109587T 2019-03-21 2020-03-20 Extracellular vesicle conjugates and uses thereof SG11202109587TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962822014P 2019-03-21 2019-03-21
US201962835439P 2019-04-17 2019-04-17
PCT/US2020/024057 WO2020191377A1 (en) 2019-03-21 2020-03-20 Extracellular vesicle conjugates and uses thereof

Publications (1)

Publication Number Publication Date
SG11202109587TA true SG11202109587TA (en) 2021-10-28

Family

ID=70296048

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109587T SG11202109587TA (en) 2019-03-21 2020-03-20 Extracellular vesicle conjugates and uses thereof

Country Status (11)

Country Link
US (1) US20240108747A1 (ko)
EP (1) EP3941528A1 (ko)
JP (1) JP2022525924A (ko)
KR (1) KR20210141554A (ko)
CN (1) CN113747925A (ko)
AU (1) AU2020241903A1 (ko)
CA (1) CA3133314A1 (ko)
IL (1) IL286562A (ko)
MX (1) MX2021011242A (ko)
SG (1) SG11202109587TA (ko)
WO (1) WO2020191377A1 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230132093A1 (en) * 2019-08-14 2023-04-27 Codiak Biosciences, Inc. Extracellular vesicle-nlrp3 antagonist
BR112022002690A2 (pt) * 2019-08-14 2022-08-23 Codiak Biosciences Inc Construtos de vesícula-aso extracelular tendo como alvo cebp/beta
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
KR102525384B1 (ko) * 2020-12-17 2023-04-24 인천대학교 산학협력단 이중 약물이 봉입된 세포외 소포체의 제조방법
CN112662695B (zh) * 2020-12-30 2021-11-26 中国医学科学院医学生物学研究所 一种细菌生物膜囊泡bbv作为疫苗载体的构建方法和应用
CN117177739A (zh) * 2021-02-17 2023-12-05 隆萨销售股份有限公司 负载细胞外囊泡的方法
JP2024506711A (ja) * 2021-02-17 2024-02-14 ロンザ セールス アーゲー 最適化リンカー及びアンカー部分を介して生物学的に活性な分子に連結した細胞外ベシクル
WO2022256201A1 (en) * 2021-06-03 2022-12-08 The Board Of Trustees Of The Leland Stanford Junior University Engineered bmp2 surrogate proteins
KR20240050387A (ko) * 2021-08-19 2024-04-18 더 리전츠 오브 더 유니버시티 오브 캘리포니아 항원 제시 세포/표적 세포 하이브리도마-유래 백신
WO2023056468A1 (en) * 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
WO2023205702A2 (en) * 2022-04-20 2023-10-26 The Board Of Trustees Of The University Of Illinois Modified exosomes and methods of use
WO2024040075A1 (en) * 2022-08-17 2024-02-22 Lonza Sales Ag Extracellular vesicle comprising a biologically active molecule and a dual cleavable linker
WO2024040076A1 (en) * 2022-08-17 2024-02-22 Lonza Sales Ag Extracellular vesicle comprising a biologically active molecule and a cell penetratng peptide cleavable linker
WO2024040073A1 (en) * 2022-08-17 2024-02-22 Lonza Sales Ag Extracellular vesicle comprising a biologically active molecule and a cleavable linker
WO2024039896A1 (en) * 2022-08-19 2024-02-22 Northeastern University Cationic peptide/protein-modified exosomes for applications in drug delivery

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
NZ503765A (en) 1997-09-12 2002-04-26 Exiqon As Bi-cyclic and tri-cyclic nucleotide analogues
ID30093A (id) 1999-02-12 2001-11-01 Sankyo Co Analog-analog nukleosida dan oligonukleotida baru
JP2002543214A (ja) 1999-05-04 2002-12-17 エクシコン エ/エス L−リボ−lna類縁体
US7087386B2 (en) 1999-06-11 2006-08-08 The Burnham Institute Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
DK2752488T3 (da) 2002-11-18 2020-04-20 Roche Innovation Ct Copenhagen As Antisense-design
US7375078B2 (en) 2004-02-23 2008-05-20 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US20060269480A1 (en) 2005-05-31 2006-11-30 Ramot At Tel Aviv University Ltd. Multi-triggered self-immolative dendritic compounds
CA2640171C (en) 2006-01-27 2014-10-28 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
WO2007134181A2 (en) 2006-05-11 2007-11-22 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
WO2008022309A2 (en) 2006-08-18 2008-02-21 F. Hoffmann-La Roche Ag Polyconjugates for in vivo delivery of polynucleotides
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
US8278425B2 (en) 2007-05-30 2012-10-02 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
EP2184355A4 (en) * 2007-08-09 2011-04-27 Daiichi Sankyo Co Ltd WITH A HYDROPHOBIC MOLECULE MODIFIED ANTIBODY
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
WO2009088401A2 (en) 2007-09-24 2009-07-16 Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Immunostimulatory combinations of tlr ligands and methods of use
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
CA2732437C (en) 2008-08-01 2017-11-21 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
DK2356129T3 (da) 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituerede alpha-L-bicykliske nukleosider
NZ597182A (en) 2009-05-22 2014-07-25 Genocea Biosciences Inc Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US20120178710A1 (en) 2009-07-01 2012-07-12 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
AU2010273220B2 (en) 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
WO2011017521A2 (en) 2009-08-06 2011-02-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
FR2950350B1 (fr) 2009-09-24 2013-12-13 Centre Nat Rech Scient Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
AP2012006253A0 (en) 2009-10-06 2012-06-30 Panacela Labs Inc Use of toll-like receptors and agonist for treating cancer.
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2588129A4 (en) 2010-06-30 2014-07-09 Univ Brandeis ON SMALL MOLECULES TARGETED PROTEIN REMOVAL
US20120219615A1 (en) 2010-10-01 2012-08-30 The Trustees Of The University Of Pennsylvania Therapeutic Use of a TLR Agonist and Combination Therapy
US20140112922A1 (en) 2011-03-28 2014-04-24 Cornell University Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes
RU2666530C2 (ru) 2012-01-12 2018-09-11 Йейл Юниверсити Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
US9221864B2 (en) 2012-04-09 2015-12-29 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
EP2846784A4 (en) 2012-05-11 2016-03-09 Univ Yale COMPOUNDS USEFUL FOR STIMULATING PROTEIN DEGRADATION AND METHODS USING THE SAME
IN2014MN02492A (ko) 2012-06-08 2015-07-17 Aduro Biotech
WO2014043544A1 (en) 2012-09-14 2014-03-20 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
EP2931738B1 (en) 2012-12-13 2019-02-06 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US9115184B2 (en) 2013-03-01 2015-08-25 The Board Of Trustees Of The Leland Stanford Junior University Light-inducible system for regulating protein stability
US20140255361A1 (en) 2013-03-07 2014-09-11 The Board Of Trustees Of The Leland Stanford Junior University Estrogen-receptor based ligand system for regulating protein stability
SG11201508165VA (en) 2013-04-29 2015-11-27 Sloan Kettering Inst Cancer Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
MX354057B (es) 2013-05-18 2018-02-09 The Regents Of The Univ Of California Star Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón".
CN105188373B (zh) 2013-05-18 2017-09-22 艾杜罗生物科技公司 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法
CA2907960C (en) 2013-05-22 2021-10-19 Children's Hospital Medical Center Combination therapy for mds
WO2015017652A1 (en) 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
US20160287623A1 (en) 2013-11-19 2016-10-06 The University Of Chicago Use of sting agonist as cancer treatment
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US10450341B2 (en) 2014-06-04 2019-10-22 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of STING
US20160022642A1 (en) 2014-07-25 2016-01-28 Yale University Compounds Useful for Promoting Protein Degradation and Methods Using Same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
EP3233882B1 (en) 2014-12-16 2019-10-30 Kayla Therapeutics Fluorinated cyclic dinucleotides for cytokine induction
US20170340658A1 (en) 2014-12-16 2017-11-30 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
MY190404A (en) 2015-03-10 2022-04-21 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
GB201504314D0 (en) 2015-03-13 2015-04-29 Univ Dundee Small molecules
WO2016149668A1 (en) 2015-03-18 2016-09-22 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
AU2016291578C1 (en) 2015-07-10 2021-07-15 Arvinas Operations, Inc. MDM2-based modulators of proteolysis and associated methods of use
US20170037004A1 (en) 2015-07-13 2017-02-09 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
GB201512733D0 (en) * 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
AU2016301196B2 (en) 2015-08-06 2022-09-08 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
WO2017024317A2 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3334745B1 (en) 2015-08-13 2024-05-15 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
GB201516243D0 (en) 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3368072A4 (en) 2015-10-28 2019-07-03 Aduro BioTech, Inc. COMPOSITIONS AND METHOD FOR ACTIVATING SIGNALING DEPENDENT ON THE STIMULATOR OF THE INTERFERON GENE
EP3370715A4 (en) 2015-11-02 2019-05-15 Yale University CHIMERIC COMPOUNDS PROVIDED AGAINST PROTEOLYSIS AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2017079723A1 (en) 2015-11-07 2017-05-11 Board Of Regents, The University Of Texas System Targeting proteins for degradation
WO2017117474A1 (en) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
WO2017117473A1 (en) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional molescules for her3 degradation and methods of use
KR20180104166A (ko) * 2016-02-09 2018-09-19 브라코 스위스 에스.에이. 셀렉틴 표적화를 위한 재조합 키메라 단백질
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
KR20180132783A (ko) 2016-04-07 2018-12-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 단백질 조절제로서 유용한 헤테로사이클릭 아미드
KR102527784B1 (ko) 2016-04-07 2023-04-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 단백질 조정제로서 유용한 헤테로시클릭 아미드
US10781205B2 (en) 2016-04-20 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
WO2017185023A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use
CN109071552B (zh) 2016-04-22 2022-06-03 达纳-法伯癌症研究所公司 细胞周期蛋白依赖性激酶4/6(cdk4/6)通过cdk4/6抑制剂与e3连接酶配体的缀合的降解及使用方法
CN109475528B (zh) 2016-04-22 2022-01-11 达纳-法伯癌症研究所股份有限公司 用于egfr降解的双功能分子和使用方法
EP3445764B1 (en) 2016-04-22 2022-06-08 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 8 (cdk8) by conjugation of cdk8 inhibitors with e3 ligase ligand and methods of use
US10059708B2 (en) 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
CN109476718B (zh) * 2016-05-18 2023-07-04 莫得纳特斯公司 编码免疫调节多肽的mrna的组合及其用途
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201610156D0 (en) 2016-06-10 2016-07-27 Otsuka Pharma Co Ltd Cliptac compositions
US11285218B2 (en) 2016-06-23 2022-03-29 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
GB201614134D0 (en) 2016-08-18 2016-10-05 Glaxosmithkline Ip Dev Ltd Novel compounds
GB2554071A (en) 2016-09-14 2018-03-28 Univ Dundee Small molecules
WO2018053354A1 (en) 2016-09-15 2018-03-22 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
PL3660004T3 (pl) 2016-10-11 2023-10-02 Arvinas Operations, Inc. Związki i sposoby do ukierunkowanej degradacji receptora androgenowego
US10689366B2 (en) 2016-11-01 2020-06-23 Cornell University Compounds for MALT1 degredation
KR20230127371A (ko) 2016-11-01 2023-08-31 아비나스 오퍼레이션스, 인코포레이티드 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
US10925868B2 (en) 2016-11-10 2021-02-23 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
WO2018098280A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
AU2017363252B2 (en) 2016-11-22 2021-08-19 Dana-Farber Cancer Institute, Inc. Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
US10925967B2 (en) 2016-11-22 2021-02-23 Dana-Farber Cancer Institute, Inc. Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
WO2018106870A1 (en) 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
MX2020001790A (es) 2017-08-25 2020-07-22 Codiak Biosciences Inc Preparacion de exosomas terapeuticos mediante el uso de proteinas de membrana.
CN107913408A (zh) * 2017-11-16 2018-04-17 中南大学 一种外泌体‑核酸适配体脂质体复合载药系统及其制备方法和应用
CN110227162A (zh) * 2019-05-15 2019-09-13 清华-伯克利深圳学院筹备办公室 靶向外泌体及制备方法、应用、药物递送系统和药物

Also Published As

Publication number Publication date
IL286562A (en) 2021-10-31
US20240108747A1 (en) 2024-04-04
CN113747925A (zh) 2021-12-03
AU2020241903A1 (en) 2021-10-14
MX2021011242A (es) 2022-01-19
WO2020191377A1 (en) 2020-09-24
KR20210141554A (ko) 2021-11-23
CA3133314A1 (en) 2020-09-24
EP3941528A1 (en) 2022-01-26
JP2022525924A (ja) 2022-05-20

Similar Documents

Publication Publication Date Title
IL286562A (en) Extracellular vesicle complexes and their uses
ZA202003833B (en) Conjugates and preparation and use thereof
IL277344A (en) Extracellular vesicles containing agonist-STING
PT3672614T (pt) Vesículas extracelulares modificadas e suas utilizações
EP3603620A4 (en) LIPOSOME COMPOSITION AND PHARMACEUTICAL COMPOSITION
EP3763233A4 (en) CLOTHING
EP3744200A4 (en) CLOTHING
EP3756493A4 (en) ARTICLE OF CLOTHING AND BRA
IL291690A (en) Extracellular vesicle assemblies
SG11202101517PA (en) Isoquinoline-steroid conjugates and uses thereof
EP3723811A4 (en) TARGETING HSP90 CONJUGATES AND FORMULATIONS OF THE LATTER
EP3599249A4 (en) ANTI-5T4-DRUG ANTIBODY CONJUGATE AND ITS USE
IL283942A (en) Tubulysins and protein-tubulysin conjugation
IL277791A (en) HSP90 targeting conjugates and their formulations
EP3705566A4 (en) IMMUNOMODULATOR COMPOSITION CONSISTING OF EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS
IL273898A (en) A vesicle-adsorbing transmembrane protein
GB201915855D0 (en) An extracellular vesicle
IL287917A (en) Hyaluronan conjugates and their uses
EP4074886A4 (en) GARMENT FOLDING DEVICE
EP3863454A4 (en) CLOTHING
EP3721866A4 (en) CATIONIZED VESICLE, AND ASSOCIATED COMPOSITION
IL290424A (en) A bracelet and its uses
EP3957787A4 (en) FABRIC AND GARMENT
EP3700533A4 (en) SSTR-TARGETING CONJUGATES AND FORMULATIONS THEREOF
GB201818562D0 (en) Pyrrolobenzodiazephones and conjugates thereof